| 1 |
Vidya Vijayan KK, Karthigeyan KP, Tripathi SP, et al. Pathophysiology of CD4＋ T-Cell Depletion in HIV-1 and HIV-2 infections[J]. Front Immunol，2017，8：580.
|
| 2 |
Padurariu-Covit MD, Chiscop I, Gutu C, et al. Retrospective analysis of HIV-associated lymphomas: insights from a single Romanian center over 15 years[J]. Front Oncol, 2025, 15: 1569433.
|
| 3 |
Noy A． Optimizing treatment of HIV-associated lymphoma[J]. Blood, 2019, 134(17): 1385-1394.
|
| 4 |
Kimani SM, Painschab MS, Horner MJ, et al. Epidemiology of haematological malignancies in people living with HIV[J]. Lancet HIV, 2020, 7(9): e641-e651.
|
| 5 |
Ikeuchi K, Saito M, Adachi E, et al. Injection drug use and sexually transmitted infections among men who have sex with men: a retrospective cohort study at an HIV/AIDS referral hospital in Tokyo, 2013-2022[J]. Epidemiol Infect, 2023, 151: e195.
|
| 6 |
Wu J, Miao Y, Qian C, et al. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: a retrospective single-center study[J]. J Cancer, 2021, 12(10): 2903-2911.
|
| 7 |
Re A, Cattaneo C, Montoto S, et al. Treatment management of haematological malignancies in people living with HIV[J]. Lancet Haematol, 2020, 7(9): e679-e689.
|
| 8 |
Baptista MJ, Garcia O, Morgades M, et al. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era[J]. AIDS, 2015, 29(7): 811-818.
|
| 9 |
Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases[J]. N Engl J Med, 2018, 378(11): 1029-1041.
|
| 10 |
中华医学会血液学分会，中国临床肿瘤学会(CSCO)抗淋巴瘤联盟. 淋巴瘤自体造血干细胞动员和采集中国专家共识(2020年版)[J]. 中华血液学杂志，2020，41(12)：979-983.
|
| 11 |
Alvarnas JC, Le Rademacher J, Wang Y, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial[J]. Blood, 2016, 128(8): 1050-1058.
|
| 12 |
Díez-Martín JL, Balsalobre P, Re A, et al. Comparable survival between HIV＋ and HIV－ non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation[J]. Blood, 2009, 113(23): 6011-6014.
|
| 13 |
Churruca J, Bastos-Oreiro M, González JS, et al. Infectious complications and mortality after autologous stem cell transplantation for lymphomas: a comparison between HIV-infected and HIV-negative patients[J]. Blood, 2016, 128(22): 2258-2258.
|
| 14 |
Hubel K, Bower M, Aurer I, et al. Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2024, 35(10): 840-859.
|
| 15 |
Hubel K, Bower M, Aurer I, et al. Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Hemasphere, 2024, 8(9): e150.
|
| 16 |
Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients[J]. Blood, 2013, 122(19): 3251-3262.
|
| 17 |
Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010[J]. Blood, 2005, 106(5): 1538-1543.
|
| 18 |
Hubel K, Re A, Boumendil A, et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party[J]. Bone Marrow Transplant, 2019, 54(10): 1625-1631.
|
| 19 |
Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy[J]. Transpl Infect Dis, 2023, 25(S1): e14109.
|
| 20 |
Saad A, Loren A, Bolaños-Meade J, et al. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022[J]. J Natl Compr Canc Netw, 2023, 21(2): 108-115.
|
| 21 |
Fattinger N, Roth JA, Baldomero H, et al. External validation of the revised pretransplant assessment of mortality score in allogeneic hematopoietic cell transplantation: a cohort study[J]. Hemasphere, 2022, 6(4): e704.
|
| 22 |
Sorror ML. How I assess comorbidities before hematopoietic cell transplantation[J]. Blood, 2013, 121(15): 2854-2863.
|
| 23 |
Damaj G, Bazarbachi A, Berning P, et al. Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee[J]. Lancet Haematol, 2025, 12(7): e542-e554.
|
| 24 |
Miller LJ, Halliday V, Snowden JA, et al. Health professional attitudes and perceptions of prehabilitation and nutrition before haematopoietic cell transplantation[J]. J Hum Nutr Diet, 2024, 37(4): 1007-1021.
|
| 25 |
Bastos-Oreiro M, Balsalobre P, Miralles P, et al. Autologous stem cell transplantation for lymphoma in HIV＋ patients: higher rate of infections compared with non-HIV lymphoma[J]. Bone Marrow Transplant, 2020, 55(9): 1716-1725.
|
| 26 |
Welz T, Wyen C, Hensel M. Drug interactions in the treatment of malignancy in HIV-infected patients[J]. Oncol Res Treat, 2017, 40(3): 120-127.
|
| 27 |
Dickter JK, Willeford CM. The management of hematopoietic stem cell transplant in people with HIV[J]. Viruses, 2024, 16(10)：1560.
|
| 28 |
Arslan S, Litzow MR, Cummins NW, et al. Risks and outcomes of allogeneic hematopoietic stem cell transplantation for hematologic malignancies in patients with HIV infection[J]. Biol Blood Marrow Transplant, 2019, 25(8): e260-e267.
|
| 29 |
Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors[J]. Blood, 2009, 114(7): 1306-1313.
|
| 30 |
Dovern E, Nijland SJAM, van Muilekom MM, et al. Physical, mental, and social health of adult patients with sickle cell disease after allogeneic hematopoietic stem cell transplantation: a mixed-methods study[J]. Transplant Cell Ther, 2023, 29(4): 283.e1-283.e9.
|
| 31 |
Pang A, Huo Y, Shen B, et al. Optimizing autologous hematopoietic stem cell transplantation for acute leukemia[J]. Stem Cells Transl Med, 2021, 10(Suppl 2): S75-S84.
|
| 32 |
中国医药生物技术协会. 自体造血干细胞移植规范[J]. 中国医药生物技术，2022，17(1)：75-93.
|
| 33 |
Cillo AR, Krishnan A, Mitsuyasu RT, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma[J]. J Acquir Immune Defic Syndr, 2013, 63(4): 438-441.
|
| 34 |
Gertz MA, Buadi FK, Hayman SR, et al. Safety outcomes for autologous stem cell transplant in multiple myeloma[J]. Mayo Clin Proc, 2018, 93(1): 56-58.
|
| 35 |
Huang SS. Chlorhexidine-based decolonization to reduce healthcare-associated infections and multidrug-resistant organisms (MDROs): who, what, where, when, and why？[J]. J Hosp Infect, 2019, 103(3): 235-243.
|
| 36 |
Commission for Hospital Hygiene and Infection Prevention (KRINKO). Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute[J]. GMS Hyg Infect Control, 2021, 64(2): 232-264.
|
| 37 |
Fehling P, Hasenkamp J, Unkel S, et al. Effect of gloved hand disinfection on hand hygiene before infection-prone procedures on a stem cell ward[J]. J Hosp Infect, 2019, 103(3): 321-327.
|